Predictive Oncology Announces Significant Progress with FluGen In the Development of First-of-Its-Kind Intranasal Flu Vaccine
PITTSBURGH, April 30, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery and biologics, announces a collaboration with FluGen to bring a first-of-its-kind intranasal flu vaccine to market, as part of a $6.2 million Phase 2B grant awarded by the United States Department of Defense (DoD).
“Predictive Oncology will play a critical role in helping to make our M2SR flu vaccine more stable and sustainable as we advance our clinical trials,” says Paul Radspinner, President & Chief Executive Officer of FluGen. “The project looks to hold tremendous promise.”
Through a proprietary design of experiments, the Predictive Oncology biologics team will be developing a formulation that is soluble and stable in a refrigerated state, which is a vital part in the drug development process. Most importantly, this addresses the need for a longer vaccine shelf-life to support global distribution including remote locations. Predictive Oncology’s biologics capabilities are uniquely suited to help achieve maximum stability, one of the initial critical milestones.
“We are excited to advance these efforts for an intranasal flu vaccine that will be unlike any other on the market,” notes Larry DeLucas, Senior Vice President of Biologics at Predictive Oncology. “Utilizing our exceptional technology and supported by our team of leading scientists, this work will allow FluGen to continue its clinical trials with greater potential to bring a more advanced and stable flu vaccine to patients.”
About Predictive Oncology
Predictive Oncology (NASDAQ: POAI) is on the cutting edge of the rapidly growing use of artificial intelligence and machine learning to expedite early drug discovery and enable drug development for the benefit of cancer patients worldwide. The company’s scientifically validated AI platform, PEDAL, is able to predict with 92% accuracy if a tumor sample will respond to a certain drug compound, allowing for a more informed selection of drug/tumor type combinations for subsequent in-vitro testing. Together with the company’s vast biobank of more than 150,000 assay-capable heterogenous human tumor samples, Predictive Oncology offers its academic and industry partners one of the industry’s broadest AI-based drug discovery solutions, further complimented by its wholly owned CLIA lab and GMP facilities. Predictive Oncology is headquartered in Pittsburgh, PA.
About FluGen:
FluGen, Inc. is a clinical-stage vaccine company transforming vaccine efficacy in infectious respiratory diseases. The company’s lead candidate is M2SR, a supra-seasonal, live, single-replication, intranasal flu vaccine. Unlike standard of care flu vaccines, M2SR stimulates mucosal, humoral, and cellular immunity. In an unprecedented challenge trial, M2SR demonstrated protection against infection and illness across seven years of virus drift; and M2SR induces a durable antibody response with potential to cover an entire flu season and beyond. M2SR also has shown activity as a vaccine vector for other respiratory vaccines and infectious diseases, including a COVID-19/flu combination. For more information about FluGen, Inc., please visit .
Contacts:
Predictive Oncology Inc.
Theresa Ferguson, Senior Director of Marketing
Phone: (630) 566-2003
Predictive Oncology Investor Relations
Tim McCarthy
LifeSci Advisors, LLC.
FluGen
Paul Radspinner
President & CEO
(608) 658-6095
Forward-Looking Statements:
Certain matters discussed in this release contain forward-looking statements. These forward- looking statements reflect our current expectations and projections about future events and are subject to substantial risks, uncertainties and assumptions about our operations and the investments we make. All statements, other than statements of historical facts, included in this press release regarding our strategy, future operations, future financial position, future revenue and financial performance, projected costs, prospects, changes in management, plans and objectives of management are forward-looking statements. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “would,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Our actual future performance may materially differ from that contemplated by the forward-looking statements as a result of a variety of factors including, among other things, factors discussed under the heading “Risk Factors” in our filings with the SEC. Except as expressly required by law, the Company disclaims any intent or obligation to update these forward-looking statements.
Acknowledgements:
The U.S. Army Medical Research Acquisition Activity, 808 Schreider Street, Fort Detrick MD 21702-5014 is the awarding and administering acquisition office.” This work was supported by The Assistant Secretary of Defense for Health Affairs endorsed by the Department of Defense, in the amount of $6,237,445 through the Peer Reviewed Medical Research Program under Award Number (HT9425-24-1-0233). Opinions, interpretations, conclusions, and recommendations are those of the author(s) and are not necessarily endorsed by The Assistant Secretary of Defense for Health Affairs endorsed by the Department of Defense. In conducting research using animals, the investigator(s) adhere(s) to the laws of the United States and regulations of the Department of Agriculture.
